KLS-13019
Product Specifications
UNSPSC Description
KLS-13019 is an orally active GPR55 receptor antagonist and a structural analogue of cannabidiol (CBD). It can prevent and reverse chemotherapy-induced peripheral neuropathy (CIPN) in a dose-dependent manner in rats[1].
Target Antigen
GPR55
Type
Reference compound
Related Pathways
GPCR/G Protein;Neuronal Signaling
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/kls-13019.html
Smiles
CC([C@@H]1CCC(C)=C[C@H]1C2=C(C=C(C=C2O)CC3CN(C3)C(C)=O)O)=C
Molecular Weight
355.47
References & Citations
[1]Ippolito MJ, et al. KLS-13019, a novel structural analogue of cannabidiol (CBD) and GPR55receptor antagonist, Prevents and Reverses Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Rats. J Pharmacol Exp Ther. 2024 Aug 22:JPET-AR-2024-002190.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-123239/KLS-13019-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-123239/
Clinical Information
No Development Reported
CAS Number
1801243-39-9
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS9227569-01 0.5 mg
Fructose 6 Phosphate Kinase Antibody (N-term) Blocking peptide
Ask
View Details 
MBS9227569-02 5x 0.5 mg
Fructose 6 Phosphate Kinase Antibody (N-term) Blocking peptide
Ask
View Details 